ReviewMedical oncology (Northwood, London, England)2026
Host chromatin architecture in HPV-driven cervical cancer: molecular mechanisms and therapeutic resistance.
Review in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent infection with high-risk human papillomavirus (HPV) is the principal etiologic driver of cervical cancer. However, HPV status and E6/E7-mediated disruption of the p53/RB axis do not fully explain why HPV-associated lesions differ in persistence, malignant progression, therapeutic response, and relapse. This review examines how host chromatin architecture and related transcriptional programs may contribute to the stabilization of malignant cell states following HPV-mediated checkpoint disruption. We discuss evidence linking HPV persistence and integration to epigenetic permissiveness, three-dimensional genome organization, enhancer-promoter rewiring, cohesin dynamics, and WAPL-associated chromatin regulation. Particular attention is given to how these mechanisms may influence MYC/E2F-centered proliferative output and cooperate with context-dependent signaling and tumor microenvironmental adaptation to contribute to treatment tolerance and resistant malignant states. We also consider how chromatin-informed biomarkers, public datasets, perturbation-guided prioritization, authenticated cervical cancer cell lines, organoids, and patient-derived models can be used to evaluate therapeutically relevant vulnerabilities. By integrating viral oncogenesis with host genome regulation and adaptive resistance, this review proposes a conceptual and experimentally testable framework for stratifying HPV-driven cervical cancer and prioritizing candidate intervention nodes.
Indexed as
Identifiers
42848106What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.